Patients with Acute Ischemic Cerebrovascular Disease with Coronary Artery Stenosis Have More Diffused Cervicocephalic Atherosclerosis

Qi Kong¹, Xin Ma¹, Chen Wang², Wuwei Feng³, Bruce Ovbiagele⁴, Yuren Zhang⁵ and Xiangying Du²

¹Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
²Department of Radiology, Xuanwu Hospital, Capital Medical University, Beijing, China
³Department of Neurology, Medical University of South Carolina, Charleston, USA
⁴Department of Neurology, University of California, San Francisco, USA
⁵Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut, USA

**Aim:** Coronary artery stenosis (CAS) ≥ 50% frequently coexists in patients with acute ischemic cerebrovascular disease (AICVD), which portends unfavorable outcomes. We sought to examine whether patients with AICVD with CAS had more severe and more diffused cervicocephalic atherosclerosis (CA).

**Methods:** Patients with AICVD were consecutively enrolled and underwent simultaneous computed tomography angiography (CTA) of the coronary and cervicocephalic arteries. A total of 140 patients were divided into “AICVD + CAS” and “AICVD only” groups according to whether CTA showed stenosis of ≥ 50% in at least one coronary arterial segment. The relationship of the presence of CAS with the severity and extent of CA were examined.

**Results:** The CA severity characteristics, including the presence of stenosis ≥ 50% and the grade of the most severe stenotic segment, were not significantly different between the two groups. Regarding the extent of CA, the presence of stenosis ≥ 50% in both sides (adjusted odds ratio [OR]: 4.29, 95% confidence interval [CI]: 1.67–10.98), both extracranial and intracranial (adjusted OR: 5.26, 95% CI: 2.24–12.35), both anterior and posterior circulation (adjusted OR: 5.29, 95% CI: 2.22–12.64), and the number of stenotic segments ≥ 50% in cervicocephalic arteries (adjusted OR: 1.58, 95% CI: 1.28–1.96) were associated with CAS in patients with AICVD, independently of clinical demographics and CA severity characteristics.

**Conclusion:** CA was similarly severe in patients with AICVD with and without CAS, but those with CAS had significantly more diffused CA. The extent of CA and CAS were mutual indicators in patients with AICVD, irrespective of CA severity.

**Key words:** Acute ischemic cerebrovascular disease, Cervicocephalic atherosclerosis, Coronary artery stenosis, Extent, Severity

---

**Introduction**

The coronary and cervicocephalic arteries are often simultaneously affected by similar vascular risk factors⁴. About 15% of patients with acute ischemic cerebrovascular disease (AICVD) had a known history of coronary artery disease⁵–⁶, whereas 18%–33% of patients with AICVD without previous coronary artery disease showed stenosis ≥ 50% on coronary angiography⁴–⁶. Compared to patients with AICVD with no coronary atherosclerosis, the risk for 2-year combined vascular events was 6.86 times for those with known coronary artery disease, and 4.36 times for those with coronary artery stenosis (CAS) ≥ 50%, but no cardiac symptoms⁷. Furthermore, the rate of stroke recurrence in patients with AICVD increased with the presence of CAS⁸. Evidence shows that the intimal medial thickness of the extracranial carotid...
arteries of patients with CAS progressed three times faster than that of patients with no CAS \(^9\). Thus, it is reasonable to postulate that CAS would indicate more serious cervicocephalic atherosclerosis (CA), leading to a higher risk of recurrent cerebral ischemic events in patients with AICVD.

Therefore, delineating the CA characteristics in patients with AICVD with CAS can be helpful to partially explain their predisposition to AICVD recurrence and to come up with appropriate monitoring and intervening solutions for patients at higher risk. Prior studies focused mainly on predicting CAS in patients with AICVD without a history of coronary artery disease, and asymptomatic CAS has been shown to be correlated with CA independently of traditional vascular risk factors \(^4, 10\). However, symptomatic CAS was also an indicator of high vascular risk \(^7\), and CA characteristics in patients with AICVD with both symptomatic and asymptomatic CAS had not been explored. Furthermore, the majority of studies examined the associations between CAS and CA severity \(^6, 10, 11\), while the extent of CA characteristics in patients with concomitant AICVD and CAS were only preliminarily investigated in a narrow range \(^4, 5\). The prognostic value of the CA extent for patients with AICVD has been highlighted in recent years \(^12, 13\), but how it is related to CAS is still unclear.

Technically, the 192-slice computed tomography (CT) is capable of simultaneously examining the coronary and cervicocephalic arteries with a lower radiation dose than the traditional CT angiography (CTA) of cervicocephalic arteries \(^14\).

**Aim**

With simultaneous coronary and cervicocephalic CTA, we aimed to test the hypothesis that patients with concomitant AICVD and CAS may have more severe and more diffused CA than patients with AICVD only.

**Methods**

This was a single-center, cross-sectional study. The hospital ethics committee approved the study and all participants provided informed consent. Patients admitted to our stroke unit from January 01, 2016 to June 30, 2016 were enrolled in this study if they meet the following selection criteria: they were 18–85 years of age; diagnosed with acute ischemic stroke or transient ischemic attack (TIA); and diagnosed within 14 days after the onset of symptoms. Patients with suspected non-atherosclerotic arterial stenosis, such as arterial dissection and vasculitis; cardioembolism or revascularization procedures; poor organ functions or hematologic diseases; and contraindications to CTA, were excluded. Patients who could not tolerate the CTA examination without interpretable images were eventually excluded from the final analysis.

**Demographics and Clinical Characteristics**

Demographic information, vascular risk factors (hypertension history, diabetes mellitus history, hypercholesterolemia history, smoking, obesity), previous acute ischemic stroke, and coronary artery disease history were recorded during a face-to-face interview. The patient was considered as smoking if they actively smoked within the last 12 months before this hospital admission \(^15\). Obesity was defined as a body mass index $\geq 30$ kg/m$^2$ at the time of admission \(^16\).

The National Institute of Health Stroke Scale was scored to assess the global deficit of the stroke. The Trial of Org 10172 in Acute Stroke Treatment criteria were used to classify acute ischemic stroke \(^17\). In addition, a stroke caused by aortic arch atherosclerosis was classified as a stroke of large-artery atherosclerosis \(^18\). All patients underwent standard blood tests, brain magnetic resonance imaging with diffusion-weighted imaging sequence or a CT scan, 12-lead electrocardiogram, and transthoracic echocardiography within 7 days after admission.

**Simultaneous Coronary and Cervicocephalic CTA**

All CTAs were performed with a dual-source 192-slice CT scanner (Somatom Force, Siemens Healthcare, Forchheim, Germany). Data were acquired in a caudocranial direction from the diaphragm to the vertex. Image acquisition was prospectively triggered by the patient's electrocardiogram and started at 30% or 60% of the R-peak to R-peak interval depending on the patient’s heart rate using the Turbo Flash Spiral mode. CT parameters were slice collimation of 192 × 0.6 mm; gantry rotation time 250 ms, and pitch 3.2. Studies were performed with automated tube current modulation (CARE Dose4D, Siemens) using a reference tube current time of 330–450 mAs. The tube voltage ranged from 70 to 90 kV using automated attenuation-based tube voltage selection (CAREkV, Siemens). The amount of contrast material (Ultravist 370 Iodine/ml; Bayer Schering Pharma, Germany) was adjusted according to the body mass index of the patient and ranged between 40 and 50 ml. The contrast agent was injected intravenously through the antebrachial vein by a power injector with a 20–22 gage needle at a flow rate of 5 mL/s, followed by a 50-mL saline chaser bolus. The contrast agent application was controlled using the bolus-tracking technique in the ascending aorta (signal
attenuation threshold, 100 HU). Data acquisition was initiated after the threshold was reached in the ascending aorta, with a mean delay of 8 s. Each raw data point was reconstructed with Advanced Model-based Iterative Reconstruction, with a slice thickness of 0.6 mm and an increment of 0.4 mm using a medium smooth reconstruction kernel (Bv36), and transferred to an external workstation (MMWP, Syngo.via, Siemens) to evaluate all CTA datasets. We recorded the dose–length–product (DLP in mGy cm) from the patient protocol for the radiation exposure, which is automatically generated for each examination.

Curved planar reformatting, maximum intensity projection, multiplanar reformatting, and volume rendering images were used to evaluate the coronary and cervicocephalic arteries. The percentage of arterial stenosis was quantified on orthogonal views with an automatic vessel analysis tool according to the North American Symptomatic Carotid Endarterectomy Trial method for the extracranial cervicocephalic arteries. The existence of CAS was confirmed when there was stenosis ≥50% in at least one coronary arterial segment ≥1.5 mm in diameter. Patients with an existing stent or a coronary artery bypass graft were considered to have CAS for this study, even their stenotic percentage could not be determined accurately. CAS without cardiac symptoms (stable angina or acute coronary artery syndrome) was defined as asymptomatic CAS.

The cervicocephalic arteries were divided into eight segments, including three extracranial segments (common carotid, extracranial carotid, extracranial vertebral arteries), two proximal intracranial segments (intracranial carotid, intracranial vertebrobasilar arteries), and three distal intracranial segments (anterior cerebral, middle cerebral, posterior cerebral arteries). Intracranial arterial stenosis was considered atherosclerotic if CTA revealed characteristics of lipid, mixed, or calcified plaques, or the patient had at least two of the following vascular risk factors: hypertension, diabetes mellitus, hypercholesterolemia, smoking, history of peripheral artery disease, history of coronary artery disease, preexisting atherosclerotic stenosis (>20%) in another location, or the presence of aortic plaques.

CA was evaluated by the severity and extent of stenosis. The presence of stenosis ≥50% in the cervicocephalic arteries and the grade of the most severe stenotic segment (0 for no stenosis; 1 for 50% stenosis; 2 for ≥50% and <70% stenosis; 3 for ≥70% stenosis; 4 for occlusion) were utilized to reflect the CA severity. Whether there was stenosis ≥50% in both sides, both extracranial and intracranial, in both anterior and posterior circulation, as well as the number of stenotic segments ≥50% in the cervicocephalic arteries, yielded a measure of CA extent.

**Grouping of Study Subjects**

After the procedure of simultaneous coronary and cervicocephalic CTA, patients were divided into “AICVD + CAS” and “AICVD only” groups according to whether CAS existed. In the subgroup analysis of patients with both AICVD and CAS, they were categorized as “AICVD with asymptomatic CAS” or “AICVD with symptomatic CAS” according to whether cardiac symptoms had presented.

**Statistical Analysis**

All statistical tests were performed using SPSS software (v17.0; IBM, Armonk, NY, United States). A P value <0.05 was considered statistically significant.

Clinical demographics and CA characteristics were compared between “AICVD + CAS” and “AICVD only” groups. Data were presented as the mean ± standard deviation for continuous variables, count (percentage) for categorical variables, and median (quartile 25%, quartile 75%) for ordinal variables. Student’s t test was used for continuous variables that are normally distributed, the Mann–Whitney U test for continuous variables that are not normally distributed, the chi-squared test for unordered categorical variables, and the rank sum test for ordinal variables.

To assess the independent associations, each CA characteristic was entered into a multivariate logistic analysis model on those demographic and clinical characteristics whose p value was <0.10 in univariate analysis. Adjusted odds ratios (ORs) for the presence of CAS were calculated with 95% confidence intervals (CIs). Multivariate logistic regression analysis was also performed to explore the age- and sex-adjusted indicative value of CAS for the presence of various CA extent characteristics.

In the predefined subgroup analysis of patients with AICVD with CAS, CA severity and extent characteristics were compared between the “AICVD with asymptomatic CAS” and “AICVD with symptomatic CAS” groups.

**Results**

A total of 179 patients with AICVD were admitted to the stroke unit. Eight patients whose symptoms...
had lasted for >14 days before admission, two patients who had cardioembolic AICVD, and one patient with suspected arterial dissection were not eligible for this study. Among the 168 eligible patients, 20 refused to participate. Of the 148 included patients, 5 could not undergo the simultaneous coronary and cervicocephalic CTA because of subsequent neurological deterioration and three patients’ CTA images were not interpretable. The remaining 140 patients were finally included in the analysis. The excluded patients were not significantly different from the patients finally included for analysis in demographics and clinical characteristics (Fig. 1).

The study subjects (132 with acute ischemic stroke and eight with TIA) had an average age of 59.3 years, with males being predominant (82.1%) (Table 1). Cervicocephalic atherosclerotic stenosis of any grade was observed in 126/140 (90.0%) patients, while stenosis ≥ 50% was revealed in 111/140 (79.3%) patients (Table 2). CAS ≥ 50% was detected in 44/140 (31.4%; including three patients with coronary stenting and two patients with coronary artery bypass grafting) patients, and 65.9% of the patients with CAS were asymptomatic. The mean DLP for simultaneous coronary and brain blood-supplying arterial CTA was 125.9 ± 30.7 mGy×cm.

Comparisons of Clinical Demographic Characteristics
Patients with CAS were more likely to be male (93.2% vs. 77.1%, p=0.021), have higher systolic blood pressure on admission (median 160 vs. 149 mmHg, p=0.044), and have positive coronary artery disease history (34.1% vs. 7.3%, p<0.001) than those without CAS. The two groups were similar in other demographics and clinical characteristics (Table 1).

Relationship of CA Severity and Extent with CAS
Compared to patients with AICVD only, the group with concomitant AICVD and CAS were more likely to have stenosis ≥ 50% in both sides (68.2% vs. 38.5%, p=0.001), in both extracranial and intracranial arteries (56.8% vs. 21.9%, p<0.001), and in both anterior and posterior circulation (61.4% vs. 26.0%, p<0.001), and the number of ≥ 50% stenotic segments tended to be larger (median 4 vs. 2, p<0.001). Regarding the CA severity characteristics, the prevalence of stenosis ≥ 50% in the cervicocephalic arteries and the grade of the most severe stenotic segments were not significantly different between the two groups (Table 2).

After adjusting for clinical demographic variables whose p value was <0.10 in univariate analysis (age, sex, history of coronary artery disease, systolic blood pressure on admission, and glycosylated hemoglobin level), the aforementioned CA extent characteristics were still correlated with CAS in patients with AICVD, whereas no independent relationship was observed between CAS and the CA severity characteristics (Table 3 Adjusted OR1). Furthermore, the presence of CAS was significantly associated with various CA extent characteristics, irrespective of the grade of the most severe stenotic segment (Table 3 Adjusted OR2). Consistent results were obtained with the additional adjustment of AICVD subtype in the multivariate logistic regression analysis (Supplemental Table 1).

Indicative Value of CAS for Diffused CA
After adjusting for age and sex, multivariate logistic regression analysis showed that the presence of CAS significantly increased the risk of having stenosis ≥ 50% in both sides (adjusted OR=3.03, 95% CI: 1.36–6.75, p=0.007), in both extracranial and intracranial arteries (adjusted OR=4.08, 95% CI: 1.83–9.10, p=0.001), and both anterior and posterior circulation (adjusted OR=4.09, 95% CI: 1.84–9.08,
Comparisons of clinical demographic characteristics between AICVD patients with and without CAS

Table 1. Comparisons of clinical demographic characteristics between AICVD patients with and without CAS

| Characteristics                  | Total (n=140) | AICVD + CAS (n=44) | AICVD only (n=96) | p value |
|----------------------------------|---------------|--------------------|-------------------|---------|
| Age (year, X ± S)                | 59.3 ± 10.4   | 61.5 ± 9.4         | 58.3 ± 10.7       | 0.087   |
| Male (n, %)                      | 115 (82.1)    | 41 (93.2)          | 74 (77.1)         | 0.021*  |
| History of HTN (n, %)            | 87 (62.1)     | 30 (68.2)          | 57 (59.4)         | 0.319   |
| History of DM (n, %)             | 50 (35.7)     | 20 (45.5)          | 30 (31.3)         | 0.103   |
| History of HLP (n, %)            | 27 (19.3)     | 5 (11.4)           | 22 (22.9)         | 0.108   |
| Smoking (n, %)                   | 71 (50.7)     | 26 (59.1)          | 45 (46.9)         | 0.180   |
| Obesity (n, %)                   | 8 (5.7)       | 2 (4.5)            | 6 (6.3)           | 0.991   |
| History of AIS (n, %)            | 33 (23.6)     | 11 (25.0)          | 22 (22.9)         | 0.787   |
| History of CAD (n, %)            | 22 (15.7)     | 15 (34.1)          | 7 (7.3)           | <0.001* |
| NIHSS on admission [M (Q25, Q75)]| 3 (1.5)       | 3 (1.5)            | 3 (1.6)           | 0.619   |
| AICVD subtype                    |               |                    |                   | 0.340   |
| TIA                              | 8 (5.7)       | 5 (6.8)            | 3 (5.2)           |         |
| Stroke of large-artery atherosclerosis | 85 (60.7) | 55 (68.2)          | 30 (57.3)         |         |
| Stroke of small-vessel occlusion | 32 (22.9)     | 26 (13.6)          | 6 (27.1)          |         |
| Stroke with two or more causes identified | 15 (10.7) | 10 (11.4)          | 5 (10.4)          |         |
| SBP on admission [mmHg, M (Q25, Q75)] | 150 (136, 161) | 160 (140, 172) | 149 (135, 160) | 0.044*  |
| DBP on admission [mmHg, M (Q25, Q75)] | 86 (80, 92)   | 89 (80, 99)        | 85 (80, 92)       | 0.163   |
| HbA1C [% M (Q25, Q75)]           | 5.75 (5.33, 7.10) | 6.20 (5.40, 7.50) | 5.70 (5.30, 6.80) | 0.077   |
| FBG [mmol/L, M (Q25, Q75)]       | 5.62 (5.04, 6.92) | 5.71 (5.06, 7.08) | 5.52 (4.97, 6.72) | 0.582   |
| Triglycerides [mmol/L, M(Q25, Q75)] | 1.36 (0.99, 1.85) | 1.46 (0.94, 2.07) | 1.32 (1.01, 1.84) | 0.782   |
| LDL-C (mmol/L, X ± S)            | 2.48 ± 0.88   | 2.60 ± 0.97        | 2.43 ± 0.84       | 0.274   |
| HDL-C (mmol/L, X ± S)            | 1.09 ± 0.29   | 1.06 ± 0.27        | 1.10 ± 0.29       | 0.481   |
| hsCRP [mg/L, M (Q25, Q75)]       | 3.56 (1.36, 5.92) | 3.18 (1.21, 10.12) | 3.71 (1.40, 5.70) | 0.844   |

*p < 0.05 was considered statistically significant.
Abbreviations: AICVD=acute ischemic cerebrovascular disease; CAS=coronary artery stenosis ≥ 50%; HTN=hypertension; DM= diabetes mellitus; HLP=hyperlipidemia; AIS=acute ischemic stroke; CAD=coronary artery disease; NIHSS=National Institute of Health Stroke Scale; TIA=transient ischemic attack; SBP=systolic blood pressure; DBP=diastolic blood pressure; HbA1C=glycosylated hemoglobin; FBG=fasting blood glucose; LDL-C=low density lipoprotein cholesterol; HDL-C=high density lipoprotein cholesterol; hsCRP=high sensitivity C reactive protein.

Table 2. Comparisons of CA characteristics between AICVD patients with and without CAS

| Characteristics                  | Total (n=140) | AICVD + CAS (n=44) | AICVD only (n=96) | p value |
|----------------------------------|---------------|--------------------|-------------------|---------|
| CA Severity                      |               |                    |                   |         |
| Presence of stenosis ≥ 50% (n, %) | 111 (79.3)    | 37 (84.1)          | 74 (77.1)         | 0.342   |
| Grade of the most severe stenotic segment [M (Q25, Q75)] | 3 (2, 4) | 3 (2, 4)          | 3 (2, 4)          | 0.175   |
| CA Extent                        |               |                    |                   |         |
| Presence of stenosis ≥ 50% in both sides (n, %) | 67 (47.9) | 30 (68.2)          | 37 (38.5)         | 0.001*  |
| Presence of stenosis ≥ 50% in both extracranial and intracranial arteries (n, %) | 46 (32.9) | 25 (56.8)          | 21 (21.9)         | <0.001* |
| Presence of stenosis ≥ 50% in both anterior and posterior circulation (n, %) | 52 (37.1) | 27 (61.4)          | 25 (26.0)         | <0.001* |
| Number of stenotic segments ≥ 50% [n, M (Q25, Q75)] | 2 (1,4) | 4 (1, 6)          | 2 (1, 3)          | <0.001* |

*p value < 0.05 was considered statistically significant.
Abbreviations: CA=cervicocephalic atherosclerosis; AICVD=acute ischemic cerebrovascular disease; CAS=coronary artery stenosis ≥ 50%.

p = 0.001) of the cervicocephalic arteries. However, the presence of CAS did not significantly affect the likelihood to have multi-segment (≥2) cervicocephalic stenosis ≥ 50% in patients with AICVD.

Then we explored the age- and sex-adjusted indicative value of CAS for having more (at least three) cervicocephalic arterial segments with stenosis ≥ 50%. All of them could be independently predicted by the presence of CAS (data not shown), where the risk of having ≥4 cervicocephalic arterial segments with stenosis ≥50% was most notably increased (adjusted OR = 6.87, 95% CI: 2.90–16.29, p < 0.001).
and clinical variables, neither extracranial nor intracranial CA severity had an independent relationship with the presence of CAS (Table 6).

**Correlation of individual Cervicocephalic Stenotic Segment ≥ 50% and CAS**

After adjusting for clinical demographic variables whose p value was < 0.10 in univariate analysis (age, sex, history of coronary artery disease, systolic blood pressure on admission, and glycosylated hemoglobin level), we found that CAS was differently connected...
Table 5. Comparisons of extra- or intracranial CA severity between AICVD patients with and without CAS

| Characteristics                                                                 | Total (n=140) | AICVD + CAS (n=44) | AICVD only (n=96) | p value |
|--------------------------------------------------------------------------------|---------------|--------------------|-------------------|---------|
| Presence of extracranial stenosis ≥ 50% (n, %)                                | 57 (40.7)     | 26 (59.1)          | 31 (32.3)         | 0.003*  |
| Presence of intracranial stenosis ≥ 50% (n, %)                               | 100 (71.4)    | 36 (81.8)          | 64 (66.7)         | 0.065   |
| Grade of the most severe extracranial stenotic segment [M (Q25, Q75)]        | 1 (0, 3)      | 2 (0, 4)           | 1 (0, 2)          | 0.003*  |
| Grade of the most severe intracranial stenotic segment [M (Q25, Q75)]        | 3 (1, 3)      | 3 (2, 3)           | 2 (1, 3)          | 0.327   |

*p value < 0.05 was considered statistically significant.
Abbreviations: CA=cervicocephalic atherosclerosis; AICVD=acute ischemic cerebrovascular disease; CAS=coronary artery stenosis ≥ 50%.

Fig. 2. Distribution of extracranial or intracranial stenosis ≥ 50% of the cervicocephalic artery in patients with AICVD with and without CAS
Abbreviations: CAS=coronary artery stenosis ≥ 50%; AICVD=acute ischemic cerebrovascular disease.

Table 6. Logistic regression analysis for the associations between CAS and extra- or intracranial CA severity in patients with AICVD

| Characteristics                                                                 | Crude OR (95%CI) | p value | Adjusted OR (95%CI)§ | p value |
|--------------------------------------------------------------------------------|------------------|---------|----------------------|---------|
| Presence of extracranial stenosis ≥ 50%                                       | 3.03 (1.45-6.33) | 0.003*  | 2.18 (0.91-5.22)     | 0.081   |
| Presence of intracranial stenosis ≥ 50%                                       | 2.25 (0.94-5.40) | 0.070   | 2.34 (0.77-7.11)     | 0.134   |
| Grade of the most severe extracranial stenotic segment                        | 1.48 (1.16-1.90) | 0.002*  | 1.31 (0.98-1.75)     | 0.071   |
| Grade of the most severe intracranial stenotic segment                         | 1.18 (0.90-1.53) | 0.229   | 1.16 (0.83-1.61)     | 0.384   |

*p value < 0.05 was considered statistically significant.
§Adjusted OR and 95%CI were calculated with adjustment of demographic and clinical variables whose p value < 0.10 in univariate analysis (age, sex, history of coronary artery disease, systole blood pressure on admission, and glycosylated hemoglobin level).
Abbreviations: CAS=coronary artery stenosis ≥ 50%; CA=cervicocephalic atherosclerosis; AICVD=acute ischemic cerebrovascular disease; OR=odds ratio; CI=confidence interval.
Table 7. Association between CAS and stenosis ≥ 50% of different cervicocephalic arterial segment in patients with AICVD

| Cervicocephalic arterial segment | AICVD + CAS (n=44) | AICVD only (n=96) | \( p \) value | Adjusted OR (95%CI) | \( p \) value |
|----------------------------------|---------------------|------------------|--------------|---------------------|--------------|
| **Extracranial segments**        |                     |                  |              |                     |              |
| Common carotid arteries          | 13 (29.5)           | 6 (6.3)          | <0.001*      | 4.52 (1.24-16.51)   | 0.023*       |
| Extracranial carotid arteries    | 16 (36.4)           | 13 (13.5)        | 0.002*       | 2.76 (1.01-7.52)    | 0.047*       |
| Extracranial vertebral arteries  | 17 (38.6)           | 16 (16.7)        | 0.004*       | 2.16 (0.82-5.66)    | 0.119        |
| **Proximal intracranial segments** |                 |                  |              |                     |              |
| Intracranial carotid arteries    | 16 (36.4)           | 13 (13.5)        | 0.002*       | 3.72 (1.37-10.11)   | 0.010*       |
| Intracranial vertebrobasilar arteries | 24 (54.5)      | 22 (22.9)        | <0.001*      | 2.86 (1.11-7.35)    | 0.029*       |
| **Distal intracranial segments** |                 |                  |              |                     |              |
| Anterior cerebral arteries       | 6 (13.6)            | 11 (11.5)        | 0.714        | 1.05 (0.31-3.64)    | 0.933        |
| Middle cerebral arteries         | 17 (38.6)           | 34 (35.4)        | 0.713        | 1.41 (0.59-3.39)    | 0.443        |
| Posterior cerebral arteries      | 23 (52.3)           | 25 (26.0)        | 0.002*       | 2.65 (1.07-6.55)    | 0.035*       |

\* \( p \) value < 0.05 was considered statistically significant.
\( \text{Comparisons of stenosis} \geq 50\% \) of different cervicocephalic arterial segment between AICVD patients with and without CAS were displayed as number (%).
\( \text{Adjusted OR and 95\%CI were calculated with adjustment of demographic and clinical variables whose } p\text{ value} < 0.10 \) in univariate analysis (age, sex, history of coronary artery disease, systole blood pressure on admission, and glycosylated hemoglobin level).

with stenosis ≥ 50% of each cervicocephalic arterial segment in patients with AICVD. For the extracranial stenosis ≥ 50%, those in the anterior circulation (common carotid, extracranial carotid arteries) rather than those in the posterior circulation (extracranial vertebral arteries) were related to CAS. For the proximal intracranial stenosis ≥ 50%, both those in the anterior and posterior circulation (intracranial carotid, intracranial vertebrobasilar arteries) were independent indicators of CAS. For the distal intracranial stenosis ≥ 50%, those in the posterior circulation (posterior cerebral arteries) instead of those in the anterior circulation (anterior cerebral, middle cerebral arteries) were associated with CAS (Table 7).

**Severity and Extent of CA in Patients with AICVD with Symptomatic and Asymptomatic CAS**

Among 44 patients with both AICVD and CAS, 15 (34.1%) patients were positive for a history of coronary artery disease, while the remaining 29 patients had no cardiac symptoms. Counterintuitively, in comparison to patients with AICVD with asymptomatic CAS, those with symptomatic CAS were inclined to have a smaller number of stenotic segments ≥ 50% (interquartile range 0–6 vs. 1.5–6.5, \( p=0.004 \)) and a lower grade of the most severe stenotic segment in cervicocephalic arteries (interquartile range 1–4 vs. 3–4, \( p=0.003 \)). Moreover, the prevalence of cervicocephalic arterial stenosis ≥ 50%, as well as the likelihood of having stenosis ≥ 50% in both sides and in both anterior and posterior circulation of the cervicocephalic arteries, was numerically larger in patients with AICVD with asymptomatic CAS (Table 8).

**Discussion**

In this cross-sectional CTA study of patients with AICVD, CA was assessed comprehensively from aspects of both severity and extent, and coronary atherosclerosis was evaluated simultaneously. We found that if CAS coexisted, the patients with AICVD distinctively tended to have more diffused stenosis in the cervicocephalic vasculature, and the extent of CA was profiled in a more multifaceted manner than that reported in the literature. Meanwhile, the CA severity was not significantly different between patients with AICVD with and without CAS.

Both symptomatic and asymptomatic CAS were indicators of high vascular risk for patients with AICVD. This study was designed to portray CA characteristics in patients with AICVD and CAS together, laying the foundation for their prognostic judgment and clinical management. Therefore, we evaluated the coronary arteries of all appropriate patients with AICVD, regardless of their cardiac symptoms. To our knowledge, only Amarenco et al. had reported the relationship between coronary atherosclerosis and CA in AICVD without the exclusion of patients who had prior cardiac symptoms. However, they assessed only the severity of extracranial carotid arteries by ultrasound to reflect CA, and patients with a history of coronary artery disease (acute coronary syndrome, myocardial infarction, or previous coronary revascularization) were grouped as
“coronary stenosis ≥ 50%” without coronary angiogram evaluation in their analysis. Notably, “positive coronary artery disease history” did not necessarily mean “coronary stenosis ≥ 50%.” As shown in our study, 7/51 (13.7%) patients with previous coronary artery disease had coronary stenosis < 50% on CTA.

Most prior studies focused on the CA severity features in patients with AICVD with CAS. The Predicting Asymptomatic Coronary Artery Disease in Patients With Ischemic Stroke and TIA (PRECORIS) study demonstrated that the severity of atherosclerosis in cervicocephalic arteries was independently associated with the prevalence of asymptomatic CAS in patients with AICVD (adjusted OR=2.3 for stenosis <50% and 3.7 for stenosis ≥50%) and developed a predictive score based on these findings. In our study, however, it seemed that CA severity characteristics had no significant relationship with coexisting CAS in patients with AICVD. Similar results were obtained when we performed the analysis only in patients with AICVD without a history of coronary artery disease. The discrepancy may be attributed to the generally serious CA in our study subjects. Of our patients, 90.0% had cervicocephalic atherosclerotic stenosis of any grade, while 79.3% had stenosis ≥50%. By contrast, these two ratios were 40% and 28%, respectively, in the PRECORIS study. Apart from racial differences (European vs. Asian), the relatively low prevalence of cervicocephalic atherosclerotic stenosis in the PRECORIS study might also be because they excluded patients with AICVD with a modified Rankin scale score ≥3, and who possibly have more severe CA.

On the other hand, as the association between CAS with extracranial stenosis had been suggested to be stronger than that of CAS with intracranial stenosis, we further respectively assessed the relationship of CAS with extracranial or intracranial CA severity characteristics. According to our data, although extracranial CA severity was more associated with CAS in comparison to intracranial CA severity in the univariate analysis, neither of them had a correlation with CAS independent of clinical demographic characteristics. Further, as demonstrated in Fig. 2, the potentially stronger association between CAS and extracranial CA severity was possibly because patients with AICVD with extracranial stenosis ≥50% were more likely to have concurrent extracranial and intracranial stenosis ≥50% than those with intracranial stenosis ≥50% (46/57 vs. 46/79). Thus, the presence of extracranial stenosis ≥50% might actually reflect a higher likelihood of patients with AICVD having diffused CA, which was an independent marker of CAS in our study.

Some prior researchers further explored the relationship between CAS and stenosis ≥50% in different segments of the cervicocephalic arteries. Arenillas et al. found that intracranial carotid artery stenosis and symptomatic vertebrobasilar stenosis, rather than stenosis in the middle cerebral and posterior arteries, were independently associated with silent myocardial ischemia among patients with symptomatic intracranial atherosclerosis. Yoo et al. observed that stenosis ≥50% of the carotid, vertebral, and basilar arteries had a closer relationship with asymptomatic CAS in patients with AICVD than that of the anterior, middle, and posterior cerebral arteries. However, cerebral angiography was largely performed with magnetic resonance angiography in these two studies (88% and 66.5%, respectively). In our research, CA of all the patients was assessed with CTA, providing a more accurate evaluation of the atherosclerotic lesions, especially those located in the original parts of the vertebral arteries, than MRA.
imal–distal and anterior–posterior location of stenosis ≥ 50% in the cervicocephalic arteries could exert significant impacts on their correlations with the presence of CAS in patients with AICVD. Therefore, the associations between CAS and cervicocephalic stenosis ≥ 50% might be present in some, but not all extracranial or intracranial arteries. This can be explained by the anatomic and physiological differences between distinct cervicocephalic arterial segments, but the definite reasons are still unknown.

Atherosclerosis is a systemic disease; theoretically, the coexistence of coronary atherosclerosis in patients with AICVD may indicate more diffused atherosclerotic lesions in the cervicocephalic vasculature. There was only preliminary research on this relationship. In a study of patients with symptomatic carotid stenosis, bilateral carotid disease was more associated with previous myocardial infarction compared to purely unilateral disease (adjusted OR = 1.7)\(^5\). Our results further manifested that bilateral cervicocephalic arterial stenosis ≥ 50% and the presence of CAS were mutually indicative in patients with AICVD.

Measuring the CA extent from another point of view, Yoo et al.\(^5\) found that multi-segment (≥ 2) cervicocephalic stenosis ≥ 50% was independently related to asymptomatic CAS in patients with AICVD (adjusted OR = 1.8). But in our study, the risk of having multi-segment (≥ 2) cervicocephalic stenosis ≥ 50% was not increased significantly with the presence of CAS, even if patients with AICVD with cardiac symptoms were excluded from the analysis. We found that patients with both AICVD and CAS tended to have a larger number of ≥ 50% stenotic segments in the cervicocephalic arteries, but the coexistence of CAS only increased the likelihood of having three or more cervicocephalic arterial segments with stenosis ≥ 50%. Thus, the distinct results with previous research might also be explained by the generally serious CA in our study. Indeed, multi-segment (≥ 2) cervicocephalic stenosis ≥ 50% was presented in 58.6% of our patients with AICVD, versus 27.7% in Yoo et al.’s study\(^5\).

Furthermore, our study showed that patients with AICVD with CAS were more likely to have stenosis ≥ 50% in both extracranial and intracranial cervicocephalic arteries, as well as in both anterior and posterior circulation. They perhaps represented a higher degree of diffused atherosclerosis than multi-segment (≥ 2) cervicocephalic stenosis ≥ 50%, serving as more sensitive CA extent markers for the coexistence of CAS in patients with AICVD, which has not been investigated before.

Why did our data manifest that CA extent but not CA severity was related to CAS in patients with AICVD? On one hand, the coexistence of AICVD and CAS might suggest an advanced and generalized atherosclerotic status; thus, it would be appropriate to use indices reflecting more serious atherosclerotic conditions to portray the characteristics of CA in examining their connections with CAS among patients with AICVD. Meanwhile, mild atherosclerotic lesions might exist in most patients with AICVD, being less discriminative between those with and without CAS. In our study, the characteristics of CA extent essentially represented diffused stenosis ≥ 50%, which were more serious than the mere presence of stenosis ≥ 50% (one characteristic of CA severity). Given that the severity and extent of CA in this study population was generally serious, perhaps only diffused cervicocephalic stenosis ≥ 50% could reach the threshold to distinguish those with and without CAS. On the other hand, we found that stenosis ≥ 50% in each cervicocephalic arterial segment was differentially associated with CAS; thus, the most severe stenotic segment might not be the most related to CAS, and the grade of the most severe stenotic segment (another characteristic of CA severity) might not parallel the possibilities of having CAS. In contrast, the characteristics of CA extent could combine atherosclerotic information from multiple segments and mitigate the differences between each segment, becoming more associated with the presence of CAS.

Notwithstanding that only the extent but not the severity of CA was related to CAS in patients with AICVD in this study, we believed that both CA severity and CA extent were important perspectives to delineate the association between coronary atherosclerosis and CA in patients with AICVD, while the statistical significance of their correlations with CAS might differ in distinct study populations and in various stages of systemic atherosclerosis. Previsously, the extent of CA was less evaluated than its severity; our work aided in offering a more integrated picture of the relationship of CA with CAS in patients with AICVD.

In addition, no study had compared the CA characteristics between patients with AICVD with symptomatic and asymptomatic CAS. We performed this analysis, but the test power was low due to the small number of patients in each subgroup. Interestingly, our data implied that patients with AICVD with asymptomatic CAS might have even more serious CA than those with symptomatic CAS. It is likely that the treatment for previous coronary artery disease had systemically ameliorated the progression of CA. Nevertheless, this observation needs to be verified by larger-scale studies and the underlying mechanism should be further probed.

Altogether, our study suggested an independent relationship of CA extent with CAS in patients with
AICVD. Just observing the CA severity could not sufficiently distinguish patients with AICVD with CAS from those without, as most patients with AICVD had severe CA. But patients with CAS might have significantly more diffused CA.

The CA extent characteristics, including stenosis ≥ 50% in both sides, both extracranial and intracranial, both anterior and posterior circulation, as well as the number of stenotic segments ≥ 50% in the cervicocephalic arteries, have been shown to be intercon- nected with unfavorable functional recovery, stroke/TIA recurrence, and combined vascular ischemic events in patients with AICVD. Cohort studies should be designed to test whether diffused CA is one of the underlying mechanisms for the poor outcomes in patients with both AICVD and CAS. Further research is needed on the utility of the close relationship between diffused CA and CAS in optimizing the risk stratification and clinical management of AICVD.

There are several limitations to this study. First, all the study subjects were enrolled from a single senior stroke unit. The sample size was not large, males were predominant, and CA was generally serious in both severity and extent. Caution must be taken in the generalizability of our results. Second, CTA is not the gold standard diagnostic tool to detect arterial stenosis, although it is one of the most accurate noninvasive angiography methods, and the CTA technology used in this study can feasibly and safely examine the coronary and cervicocephalic arteries at the same time. Third, some arterial stenosis in this study might not be atherosclerotic, but caused by other pathologies, although we carefully searched for other possible reasons for cervicocephalic arterial stenosis and excluded the suspected patients.

**Conclusion**

Patients with AICVD with CAS tended to have more diffused CA than those without CAS, although they might have equally severe cervicocephalic arterial stenosis. The CA extent correlated with CAS in patients with AICVD, regardless of CA severity. A comprehensive evaluation of CA from aspects of both extent and severity is important to reveal and further utilize the associations between coronary atherosclerosis and CA in patients with AICVD.

**Acknowledgments**

This study is grant supported by the Beijing Municipal Administration of Hospitals Clinical Medicine Development (Grant No: ZY LX201706), Beijing Municipal Natural Science Foundation (Grant No: 7172093), and Clinical Center for Cardio-cerebrovascular Disease of Capital Medical University.

**Conflict of Interest**

None.

**References**

1) Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P, Taubert KA: Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke, 2003; 34: 2310-2322

2) Meng X, Chen Y, Jing J, Zhao X, Wang C, Liu L, Wang A, Pan Y, Li C, Wang Y: Association between polyvascular atherosclerosis and estimated glomerular filtration rate in patients with ischemic stroke: data analysis of the patients in the Chinese National Stroke Registry. Neurou Res, 2015; 37: 415-420

3) Hoshino T, Sissani L, Labreuche J, Ducrocq G, Lavallee PC, Meseguer E, Guidoux C, Cabrelo H, Hobeau C, Gongora-Rivera F, Touboul PJ, Steg PG, Amarenco P: Prevalence of Systemic Atherosclerosis Burdens and Overlapping Stroke Etiologies and Their Associations With Long-term Vascular Prognosis in Stroke With Intracranial Atherosclerotic Disease. Jama Neurol, 2018; 75: 203-211

4) Calvet D, Touze E, Varenne O, Sablerylles JL, Weber S, Mas JL: Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: the PRECORS study. Circulation, 2010; 121: 1623-1629

5) Yoo J, Yang JH, Choi BW, Kim YD, Nam HS, Choi HY, Cho HJ, Lee HS, Cha MJ, Choi D, Nam CM, Jang Y, Lee DH, Kim J, Heo JH: The frequency and risk of preclinical coronary artery disease detected using multichannel cardiac computed tomography in patients with ischemic stroke. Cerebrovasc Dis, 2012; 33: 286-294

6) Amarenco P, Lavallee PC, Labreuche J, Ducrocq G, Juliard JM, Feldman L, Cabrelo H, Meseguer E, Guidoux C, Adrai V, Ratani S, Kusmierek J, Lapergue B, Klein IF, Gongora-Rivera F, Jaramillo A, Mazighi M, Touboul PJ, Steg PG: Prevalence of coronary atherosclerosis in patients with cerebral infarction. Stroke, 2011; 42: 22-29

7) Amarenco P, Lavallee PC, Labreuche J, Ducrocq G, Juliard JM, Feldman L, Cabrelo H, Meseguer E, Guidoux C, Adrai V, Ratani S, Kusmierek J, Lapergue B, Klein IF, Gongora-Rivera F, Jaramillo A, Aboud H, Olivot JM, Mazighi M, Touboul PJ, Steg PG: Coronary artery disease and risk of major vascular events after cerebral infarction. Stroke, 2013; 44: 1505-1511

8) Yoo J, Song D, Baek JH, Kim K, Kim J, Song TJ, Lee HS, Choi D, Kim YD, Nam HS, Heo JH: Poor long-term outcomes in stroke patients with asymptomatic coronary artery disease in heart CT. Atherosclerosis, 2017; 265: 7-13

9) Crouse JR, Tang R, Espeland MA, Terry JG, Morgan T,
Mercuri M: Associations of extracranial carotid atherosclerosis progression with coronary status and risk factors in patients with and without coronary artery disease. Circulation, 2002; 106: 2061-2066
10) Calvet D, Song D, Yoo J, Turc G, Sablyrolles JL, Choi BW, Heo JH, Mas JL: Predicting asymptomatic coronary artery disease in patients with ischemic stroke and transient ischemic attack: the PRECORS score. Stroke, 2014; 45: 82-86
11) Seo WK, Yong HS, Koh SB, Suh SI, Kim JH, Yu SW, Lee JY: Correlation of coronary artery atherosclerosis with atherosclerosis of the intracranial cerebral artery and the extracranial carotid artery. Eur Neurol, 2008; 59: 292-298
12) Lau AY, Wong KS, Lev M, Furie K, Smith W, Kim AS: Burden of intracranial steno-occlusive lesions on initial computed tomography angiography predicts poor outcome in patients with acute stroke. Stroke, 2013; 44: 1310-1316
13) Kim BS, Chung PW, Park KY, Won HH, Bang OY, Chung CS, Lee KH, Kim GM: Burden of Intracranial Atherosclerosis Is Associated With Long-Term Vascular Outcome in Patients With Ischemic Stroke. Stroke, 2017; 48: 2819-2826
14) K S, RJ H, LJ W, C W, N C, XY D, LG L, KC L: Feasibility of high-pitch dual-source CT combined with carotid and cerebrovascular angiography. Chin J Med Imaging Technol, 2014; 30: 136-140
15) Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselii GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorelie P, Yancy CW, Rosamond WD: Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation, 2010; 121: 586-613
16) Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich hhMW, Richardson D, Schwamm LH, Wilson JA: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2014; 45: 2160-2236
17) Adams HJ, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh ER: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 1993; 24: 35-41
18) Gao S, Wang YJ, Xu AD, Li YS, Wang DZ: Chinese ischemic stroke subclassification. Front Neurol, 2011; 2: 6
19) North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. Stroke, 1991; 22: 711-720
20) Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimoowitz MI: A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol, 2000; 21: 643-646
21) Mazighi M, Tanasescu R, Ducrocq X, Vicaut E, Bracard S, Houdart E, Woimant F: Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology, 2006; 66: 1187-1191
22) Conforto AB, Leite CC, Nomura CH, Bor-Seng-Shu E, Santos RD: Is there a consistent association between coronary heart disease and ischemic stroke caused by intracranial atherosclerosis? Arq Neuropsiquiatr, 2013; 71: 320-326
23) Arenillas JF, Candell-Riera J, Romero-Farina G, Molina CA, Chacon P, Aguade-Bruix S, Montaner J, de Leon G, Castell-Conesa J, Alvarez-Sabin J: Silent myocardial ischemia in patients with symptomatic intracranial atherosclerosis: associated factors. Stroke, 2005; 36: 1201-1206
24) Bash S, Villablanca JP, Jahan R, Duckwiler G, Tillis M, Kidwell C, Saver J, Sayre J: Intracranial vascular stenosis and occlusive disease: evaluation with CT angiography, MR angiography, and digital subtraction angiography. AJNR Am J Neuroradiol, 2005; 26: 1012-1021
25) Khan S, Cloud GC, Kerry S, Markus HS: Imaging of vertebral artery stenosis: a systematic review. J Neurol Neurosurg Psychiatry, 2007; 78: 1218-1225
26) Touze E, Warlow CP, Rothwell PM: Risk of coronary and other nonstroke vascular death in relation to the presence and extent of atherosclerotic disease at the carotid bifurcation. Stroke, 2006; 37: 2904-2909
27) Sacco RL, Wolf PA, Kannel WB, McNamara PM: Survival and recurrence following stroke. The Framingham study, Stroke, 1982; 13: 290-295
28) Hur J, Lee KH, Hong SR, Suh YJ, Hong YJ, Lee HJ, Kim YJ, Lee HS, Chang HJ, Choi BW: Prognostic value of coronary computed tomography angiography in stroke patients. Atherosclerosis, 2015; 238: 271-277
### Supplemental Table 1. Logistic regression analysis for the associations between CAS and CA characteristics in AICVD patients with additional control of ACIVD subtype

| Characteristics                                      | Adjusted OR (95%CI) | p value |
|------------------------------------------------------|---------------------|---------|
| CA Severity                                          |                     |         |
| Presence of stenosis ≥ 50%                           | 1.55 (0.44-5.48)    | 0.497   |
| Grade of the most severe stenotic segment            | 1.12 (0.77-1.64)    | 0.561   |
| CA Extent                                            |                     |         |
| Presence of stenosis ≥ 50% in both sides             | 2.69 (1.01-7.18)    | 0.048*  |
| Presence of stenosis ≥ 50% in both extracranial and intracranial arteries | 2.94 (1.14-7.57)    | 0.026*  |
| Presence of stenosis ≥ 50% in both anterior and posterior circulation | 3.80 (1.39-10.39) | 0.009*  |
| Number of stenotic segments ≥ 50%                    | 1.33 (1.08-1.64)    | 0.009*  |

* p value < 0.05 was considered statistically significant.

*Adjusted OR and 95%CI were calculated with adjustment of demographic and clinical variables whose p value < 0.10 in univariate analysis (age, sex, history of coronary artery disease, systole blood pressure on admission, and glycosylated hemoglobin level) and AICVD subtype. Abbreviations: CAS=coronary artery stenosis ≥ 50%; CA=cervicocephalic atherosclerosis; AICVD=acute ischemic cerebrovascular disease; OR=odds ratio; CI=confidence interval.